 |
Myriad Genetics Announces First Quarter Fiscal 2007 Financial Results Conference Call
Oct 24, 2006
|
4.8 KB |
|
| |
Salt Lake City, October 24, 2006—Myriad Genetics, Inc.
(Nasdaq: MYGN) (www.myriad.com)
has arranged a conference call with the management
team to provide a company update. Peter Meldrum, President and Chief
Executive Officer will host the call along with Jay M...
|
|
Myriad Genetics Reports Financial Results for Fiscal 2006
Aug 22, 2006
|
9.7 KB |
|
| |
Salt Lake City, August 22, 2006—Myriad Genetics, Inc.
(Nasdaq: MYGN)
(www.myriad.com) today
reported financial results for its fourth quarter and
fiscal year ended June 30, 2006.
In fiscal 2006, predictive medicine product revenues increased to a record
$100.6 ...
|
|
Myriad Genetics Completes Enrollment in U.S. Phase 3 Clinical Trial of Flurizan for Alzheimer's Disease
Aug 22, 2006
|
7.4 KB |
|
| |
Salt Lake City, August 22, 2006—Myriad Genetics, Inc.
(Nasdaq: MYGN) (www.myriad.com) announced today that it has completed enrollment in its U.S.
Phase 3 clinical trial of Flurizan™ for patients with Alzheimer's disease.
The U.S. Phase 3 trial is th...
|
|
Myriad Genetics Announces Fourth Quarter and Fiscal Year-end 2006 Financial Results Conference Call
Aug 8, 2006
|
5.0 KB |
|
| |
Salt Lake City, August 8, 2006—Myriad Genetics,
Inc. (NASDAQ: MYGN) (www.myriad.com) has arranged a conference call with the management
team to provide a company update. Peter Meldrum, President and Chief
Executive Officer will host the call along with Jay Moyes,...
|
|
Myriad Introduces Enhanced BRACAnalysis® Test for Exceptionally High-Risk Breast Cancer Patients
Aug 1, 2006
|
6.8 KB |
|
| |
Salt Lake City, August 1, 2006—Myriad Genetics, Inc.
(Nasdaq: MYGN)
(www.myriad.com) announced today the introduction of the
BRACAnalysis® Rearrangement Test, a new molecular diagnostic test in the
BRACAnalysis family of products. The add...
|
|
Myriad's 24-Month Study of Flurizan Demonstrates Significant Benefit in Alzheimer's Disease Patients
Jul 29, 2006
|
10.8 KB |
|
| |
Salt Lake City, July 19, 2006—Myriad Genetics, Inc.
(Nasdaq: MYGN)
(www.myriad.com) announced today that results of its completed
Phase 2 follow-on study of Flurizan™ in patients with mild Alzheimer's
disease were presented at the 10th International Confe...
|
|
Myriad Genetics Begins Phase 1 Trial of Anti-Thrombin Drug MPC-0920
May 2, 2006
|
8.9 KB |
|
| |
Salt Lake City, May 2, 2006—Myriad Genetics, Inc.
(Nasdaq: MYGN)
(www.myriad.com) has initiated a Phase 1 human clinical trial of MPC-0920, an
orally available, direct thrombin inhibitor. The trial will enroll healthy
volunteers in a single, escalating dose form...
|
|
Myriad Genetics Reports Results for Third Quarter of Fiscal 2006
May 2, 2006
|
10.3 KB |
|
| |
Salt Lake City, May 2, 2006—Myriad Genetics, Inc.
(Nasdaq: MYGN)
(www.myriad.com) today reported consolidated financial results for the third
quarter of fiscal 2006 and the nine months ended March 31, 2006.
Total revenues in the third quarter of fiscal ...
|
|
Myriad Genetics Announces Third Quarter Fiscal 2006 Financial Results Conference Call
Apr 18, 2006
|
5.2 KB |
|
| |
SALT LAKE CITY, April 18, 2006–Myriad Genetics,
Inc. (Nasdaq: MYGN)
(www.myriad.com) has arranged a conference call with the management
team to provide a company update. Peter Meldrum, President and Chief
Executive Officer will host the call along with Jay Moyes...
|
|
Myriad and Abbott Enter Into Broad Discovery Collaboration
Apr 11, 2006
|
6.8 KB |
|
| |
Salt Lake City, April 11, 2006 – Myriad Genetics, Inc.
(Nasdaq: MYGN)
(www.myriad.com)
and Abbott (NYSE: ABT) (www.abbott.com)
announc...
|
|
Myriad Genetics' Follow-on Study of Flurizan Demonstrates Continued Benefit in Alzheimer's Disease
Mar 12, 2006
|
9.2 KB |
|
| |
Salt Lake City, March 12 – Myriad Genetics, Inc.
(Nasdaq: MYGN) (www.myriad.com)
announced today that data from its Phase 2
follow-on study of Flurizan™ in patients with mild Alzheimer's disease is
being presented at the 19th annual meeting of the America...
|
|
Myriad Pharmaceuticals, Inc. Names Vice President of Marketing
Mar 8, 2006
|
6.3 KB |
|
| |
SALT LAKE CITY, March 8 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc.
(Nasdaq: MYGN) (www.myriad.com ) announced today that Jose Fojas has been
appointed Vice President of Marketing for Myriad Pharmaceuticals, Inc.
Mr. Fojas will oversee all aspects of marketing therapeutic compounds at
Myriad, including marketing plans, forecasts ...
|
|
Myriad Genetics Reports Results for Second Quarter of Fiscal 2006
Feb 7, 2006
|
10.1 KB |
|
| |
SALT LAKE CITY, February 7, 2006 – Myriad Genetics, Inc.
(Nasdaq: MYGN)
(www.myriad.com) today reported
financial results for the second quarter of
fiscal 2006 and the six months ended December 31, 2005.
For the second fiscal quarter of 2006, total rev...
|
|
Myriad Genetics Announces Second Quarter Fiscal 2006 Financial Results Conference Call
Jan 31, 2006
|
4.8 KB |
|
| |
SALT LAKE CITY, January 31, 2005 – Myriad Genetics, Inc.
(Nasdaq: MYGN) (www.myriad.com)
has arranged a conference call with the management
team to provide a company update. Peter Meldrum, President and Chief
Executive Officer will host the call along with Jay M...
|
|
Myriad Genetics and Abbott Extend Collaboration
Nov 22, 2005
|
7.6 KB |
|
| |
SALT LAKE CITY, November 22, 2005 – Myriad Genetics, Inc.
(Nasdaq: MYGN) (www.myriad.com), and Abbott (NYSE: ABT) have extended their
strategic alliance in pharmacogenetics, the Company announced today. The
resea...
|
|
Myriad Genetics' Follow-on Study of Flurizan™ Demonstrates Cognitive Improvement in Alzheimer's Disease
Nov 15, 2005
|
10.5 KB |
|
| |
Salt Lake City, November 15, 2005 – Myriad Genetics, Inc.
(Nasdaq: MYGN) announced today that an analysis of data from its Phase 2 follow-on study of Flurizan™ in patients with mild Alzheimer's disease showed that study participants improved as a group, regaining cognitive ability from months 12...
|
|
Myriad Genetics Announces Exercise of Over-Allotment Option by Underwriters of Public Offering
Nov 8, 2005
|
4.3 KB |
|
| |
Salt Lake City, November 8, 2005 – Myriad Genetics, Inc.
(Nasdaq: MYGN) today announced that the underwriters have exercised in full
their over-allotment option to purchase 1,050,000 additional shares of common
stock at a public offering price of $18.50 per share. The closing of the
purchase of th...
|
|
Myriad Genetics Announces Pricing of Common Stock Offering
Nov 3, 2005
|
4.3 KB |
|
| |
Salt Lake City, November 03, 2005 – Myriad Genetics, Inc.
(Nasdaq: MYGN) today announced the pricing of its public offering of 7,000,000
shares of its common stock at an offering price of $18.50 per share. Myriad
has granted the underwriters a 30-day option to purchase an additional
1,050,000 shar...
|
|
Myriad Genetics Commences Offering of Common Stock
Oct 28, 2005
|
4.1 KB |
|
| |
Salt Lake City, October 28, 2005 – Myriad Genetics, Inc.
(Nasdaq: MYGN) today announced that it had commenced an underwritten public
offering of 7,000,000 shares of its common stock pursuant to an effective
shelf registration statement. Myriad also expects to grant the underwriters a
30-day option...
|
|
Myriad Genetics, Inc. Reports Results for First Quarter of Fiscal 2006
Oct 26, 2005
|
10.4 KB |
|
| |
Salt Lake City, October 26, 2005 – Myriad Genetics, Inc.
(Nasdaq: MYGN) today reported financial results for the first quarter of
fiscal 2006. For the three-month period ended September 30, 2005, predictive
medicine revenues increased to $21.5 million from $14.4 million in the same
quarter of the ...
|
|
|
